Prognostic value of the 6-min walk test derived attributes in patients with idiopathic pulmonary fibrosis.

Introduction: Idiopathic pulmonary fibrosis (IPF) is a fatal progressive fibrosing lung disease. A decreased 6-min walk distance (6MWD) and exercise-induced oxygen desaturation measured during the 6-min walk test (6MWT), are known predictors of mortality in patients with IPF. However, the use of antifibrotic drugs showed a survival benefit in IPF. Therefore, this study aimed to evaluate to what extend 6MWT-derived attributes are associated with two-year survival when antifibrotic drugs were introduced as part of standard IPF-care.
Methods: This real-world data-study included patients with IPF with a 6MWT between 2015 and 2020, and used composite outcome: mortality or lung transplantation within 2 years of follow-up. Data were collected systematically, including demographics, pulmonary function tests, comorbidities, medications and 6MWT-derived attributes. The prediction attributes of 6MWT were studied with a Cox Proportional-Hazards model and Kaplan-Meier survival curves. The best discriminating attribute to predict mortality was added to the prediction model Gender-Age-Physiology (GAP).
Results: In 216 patients, 2-year transplant-free survival cut-off points were identified for the 6MWD (≥413 m), 6MWD %predicted (≥83 %), SpO ₂ -nadir (≥86 %) and distance-saturation-product (≥374 m%), with the best discriminative value for SpO ₂ -nadir (area under the curve: 0.761). 2-Year survival percentage of patients with SpO ₂ -nadir below or above threshold (86 %) was 37.1 % and 80.0 %, respectively. Exercise-induced oxygen desaturation added to the GAP model showed an improvement in its predictive power.
Conclusion: Patients with IPF who have an exercise-induced oxygen desaturation have worse prognosis. Addition of SpO ₂ -nadir to the GAP model seems promising for use in clinical care of IPF patients.
Competing Interests: Declaration of competing interest The author declares on behalf of all authors that they have no relevant or material financial interests related to the research described in this article.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)